Market Research Report: Cepheid

Company Overview

• Name: Cepheid

• Mission: Delivering a Better Way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere.

• Founding Year and Founders: Founded in 1996.

• Key People:

• Vitor Rocha, President

• Laurent Bellon, Ph.D., Senior Vice President, Research & Development

• Scott Campbell, Senior Vice President, Regulatory and Clinical Affairs

• Peter Farrell, Executive Vice President, Worldwide Commercial Operations

• David H. Persing, M.D., Ph.D., EVP and Chief Medical and Scientific Officer

• Headquarters: Sunnyvale, California, USA. European headquarters in Maurens-Scopont, France.

• Employees: No information is available.

• Revenue: No information is available.

• Notable For: Known for pioneering molecular diagnostics that streamline complex procedures and provide accurate, rapid test results, particularly in infectious diseases and oncology.

Products

GeneXpert® System

• Description: A flexible, scalable platform offering a range of diagnostic tests.

• Key Features:

• Integrated sample preparation, amplification, and detection.

• Available in multiple configurations for different settings, from core labs to near-patient applications.

Xpert® Tests

• Xpert Xpress SARS-CoV-2 (EUA): Rapid test for the detection of SARS-CoV-2.

• Xpert Xpress Strep A: Test for Group A Streptococcus.

• Xpert Xpress Flu/RSV: Diagnostic test for flu and respiratory syncytial virus.

• Xpert MTB/RIF: Test for TB and rifampicin resistance.

• Xpert MRSA NxG: Test for Methicillin-resistant Staphylococcus aureus.

Additional Product Categories

• Sexual Health: Includes tests like Xpert TV and Xpert CT/NG.

• Healthcare Associated Infections: Tests for MRSA, C. difficile, and Norovirus.

• Oncology/Genetics: Xpert BCR-ABL Ultra and Xpert FII & FV for cancer and genetic testing.

Recent Developments

• New Products/Features:

• Xpert Mpox: Received Emergency Use Listing by WHO and a U.S. FDA Emergency Use Authorization for diagnosing mpox.

• New Partnerships:

• Fleming Initiative Partnership: A global collaboration to tackle antimicrobial resistance, focusing on enhancing diagnostics and encouraging responsible antibiotic use.

• Innovations:

• Expansion in decentralized testing capabilities with devices like GeneXpert Xpress suitable for near-patient applications.

Conclusion

Cepheid's advancement in molecular diagnostics highlights its dedication to improving healthcare outcomes via enhanced diagnostic accuracy and accessibility. With strategic partnerships and product innovations like the Xpert Mpox amidst global health challenges, Cepheid aligns with urgent public health needs.